PT-141 (Bremelanotide) Injection

*Actual vial appearance, contents, and dosage may vary and is based on your prescription.

PT-141 (Bremelanotide) Injection

PT-141, also known as bremelanotide, is a synthetic peptide derived from melanocortin receptor research. Unlike therapies that act primarily on vascular pathways, PT-141 has been studied for its interaction with central nervous system signaling, particularly melanocortin receptors involved in sexual desire and arousal pathways. PT-141 is administered via subcutaneous injection and works independently of nitric oxide–mediated mechanisms. (Overview review: https://pubmed.ncbi.nlm.nih.gov/28778618/)
Free Shipping
Medical Consultation Included
  • Injectable formulation (subcutaneous injection)
  • Available in 48 states (excluding Alabama and Mississippi)
  • No hidden membership, consultation, or shipping costs
  • Care reviewed by a licensed provider in your state
  • Prescription issued only when clinically appropriate

Educational only; outcomes are not guaranteed.

Supports Sexual Desire Signaling Pathways

PT-141 has been studied for its action on melanocortin receptors in the brain, which are involved in sexual desire and arousal signaling rather than direct blood-flow mechanisms.
https://pubmed.ncbi.nlm.nih.gov/28778618/

Works Independently of Nitric Oxide Pathways

Unlike PDE-5 inhibitors, PT-141 does not rely on nitric oxide or vascular dilation, making it mechanistically distinct in research literature.
https://pubmed.ncbi.nlm.nih.gov/21427119/

Studied in Both Men and Women

Clinical studies have evaluated PT-141 in male and female populations for effects related to sexual desire and arousal under specific conditions.
https://pubmed.ncbi.nlm.nih.gov/19887552/

Central Nervous System–Focused Mechanism

PT-141’s mechanism of action is centered on hypothalamic and limbic pathways associated with motivation and desire.
https://pubmed.ncbi.nlm.nih.gov/17009063/

Explored for Psychogenic Sexual Dysfunction Pathways

Research has examined PT-141 in populations where psychological or neurologic signaling plays a role in sexual response.
https://pubmed.ncbi.nlm.nih.gov/21427119/

  • Initial 3-month care period
  • Designed to support appropriate use, monitoring, and consistency of care
  • Ongoing care options available following the initial period, with the ability to manage or discontinue thereafter

  • Clinical review typically completed within 24 hours
  • Pharmacy processing may take 2–7 business days, depending on availability
  • Once dispensed, PT-141 injection is shipped via 2-day delivery

PT-141 injections are prescribed by licensed healthcare providers based on an individual clinical evaluation and medical eligibility. Compounded formulations are not FDA-approved, and their safety and effectiveness have not been independently evaluated by the FDA.

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.


Important Note:

Information provided is for educational purposes only and does not constitute medical advice. All care and prescriptions are provided solely at the discretion of a licensed healthcare provider following an individual evaluation.

Stories from Our Community

Hear from individuals who chose a more guided, informed approach to their wellness journey.

GLP 1 + B12

GLP 1 + B12

I appreciated how everything was explained clearly, step by step, from the very beginning. The process never felt rushed or confusing, and there was no pressure at any point. Instead, the guidance helped me understand my options and feel comfortable moving forward at my own pace.

A Celara Med User

GLP 1 + B12

GLP 1 + B12

I appreciated how everything was explained clearly, step by step, from the very beginning. The process never felt rushed or confusing, and there was no pressure at any point. Instead, the guidance helped me understand my options and feel comfortable moving forward at my own pace.

A Celara Med User

frequently asked questions

Quick answers to common questions, designed to help you feel clear and confident as you explore Celara Med.

No. PT-141 is not a hormone and does not affect testosterone or estrogen levels. It works through central nervous system signaling pathways.
https://pubmed.ncbi.nlm.nih.gov/28778618/

No. PT-141 does not work through vascular dilation or nitric oxide pathways. Its mechanism is centrally mediated rather than blood-flow based.
https://pubmed.ncbi.nlm.nih.gov/21427119/

Adults experiencing concerns related to sexual desire or arousal signaling may be evaluated by a licensed healthcare provider. Eligibility is determined through individual clinical review.

PT-141 is administered via subcutaneous injection, as directed by a licensed healthcare provider. Instructions are provided during onboarding.

Some individuals may experience temporary side effects such as nausea, flushing, headache, increased blood pressure, or injection site irritation. Side effects vary and should be discussed with a provider.

In some cases, a provider may approve PT-141 in combination with other wellness or sexual-health–focused therapies, depending on individual needs and clinical appropriateness.

PT-141 injections through Celara Med are available in 48 states, excluding Alabama and Mississippi, subject to provider licensure and state regulations.

Yes. PT-141 is offered within a structured care plan designed to support appropriate use, monitoring, and clinical oversight.